Overview
Updated 14 Jul 2026
Michael A. Morse, MD, is Professor of Medicine (Medical Oncology), Professor in the Department of Surgery at Duke University School of Medicine / Duke Cancer Institute. The public record shows 552 publications with 28,410 citations (h-index 82), centered on Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 18 registered clinical trials, industry payments reported by 33 companies, 3 NIH-funded awards (2001–2008).
- Most recent indexed publication: 2025 · Science immunology
- Top research focus: Immunotherapy and Immune Responses
- 18 registered trials on ClinicalTrials.gov
- Open Payments reporting from 33 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 283.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 18 registered studies on ClinicalTrials.gov. The most recent:
- Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
Sponsor: Duke University
InvestigatorPhase 1/PHASE2CompletedNCT03043664 - Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines
Sponsor: Duke University
InvestigatorPhase 2TerminatedNCT02159482 - Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
Sponsor: Duke University
InvestigatorPhase 1CompletedNCT01890213
Industry payments
Updated 14 Jul 2026
33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year202598 payments$96,438openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202551 payments$77,963openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year202546 payments$68,763openpaymentsdata.cms.gov ↗
NIH funding
Updated 14 Jul 2026
3 NIH research awards on record, funded 2001–2008 per NIH RePORTER. The latest:
Congress activity
Updated 14 Jul 2026
114 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 5296: Enhancing the strength and durability of vaccine-induced anti-tumor immunity with CD27 agonism of CD4+ T cells
AACR Annual Meeting
AACR2024Co-author - Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer.
ASCO Annual Meeting
ASCO2024Co-authorOnline-only
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians.
CA: a cancer journal for clinicians
2025
Most-cited worksby citation count (OpenAlex)
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Seeley G. Mudd Building, Room 437, 10 Bryan Searle Drive, Durham, NC 27710
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
- Board Certified
Internal Medicine, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗ - Board Certified
Medical Oncology, American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗ - Board Certified
Hematology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dukehealth.org ↗
Editorial & leadership rolesjournal and society appointments
- Editor-in-Chief
Expert Opinion on Biological Therapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗ - Associate Editor
Clinical Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗ - Associate Editor
Cancer Investigation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗
Awards & honorshonors on the public record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beattheboards.com ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/michael-morse-md-dccc1472
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by otherswhere others cite or feature them
- Other
netrf.org/specialist/dr-michael-morse-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →netrf.org ↗ - Other
onclive.com/authors/michael-morse-md-duke-cancer-institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
Universitair Ziekenhuis Leuven
- 1,845
- publications
- 177
- h-index
- 14
- trials
Josep Tabernero, MD, PhD
Vall d'Hebron Institut de Recerca
- 2,704
- publications
- 148
- h-index
- 19
- trials
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Charles Fuchs, MD, MPH
Yale Cancer Center
- 1,721
- publications
- 172
- h-index
- 7
- trials